Prostate Cancer
Provenge Registry for Advanced Prostate Cancer
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED)
| Status | Conditions | Phase | Study ID |
| Recruiting | Advanced Prostate Cancer | NA | NCT01306890 |
Summary
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival.
|
|
Eligibility Criteria (must meet the following to participate in this study)
- Subjects must be at least 18 years of age.
- Subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ≤ 6 months prior to enrollment.
- Subjects must understand and sign an informed consent form.
Last Updated
October 15, 2012See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
Join Us On